Drugs / Betuvax-CoV-2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05270954 Comparator | Oct 2021 → Apr 2022 | COVID-19 | Artgen Biotech | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Betuvax-CoV-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05270954 ↗ |
| Modality | Vaccine | “Recombinant COVID-19 Vaccine Betuvax-CoV-2” NCT05270954 ↗ |
| Route | Intramuscular | “Betuvax-CoV-2 intramuscular injection solution” NCT05270954 ↗ |